| Field | Specification |
|---|---|
| Target | |
| Alternative names | Insulin-like growth factor 2 mRNA-binding protein 1; IGF2 mRNA-binding protein 1; IMP-1; IMP1; Coding region determinant-binding protein; CRD-BP; IGF-II mRNA-binding protein 1; VICKZ family member 1; Zipcode-binding protein 1; ZBP-1; IGF2BP1; CRDBP; VICKZ1; ZBP1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human IMPI/IGF2BP1 recombinant protein (Position: N8-Q562). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets insulin-like growth factor 2 mRNA-binding protein 1 (gene IGF2BP1) in human samples and is validated for Western blot, flow cytometry and ELISA. The predicted molecular weight is 63.5 kDa, and the supplier reports an observed band at about 63 kDa.
IGF2BP1 (also called IMP1 or ZBP1) is an RNA-binding protein that packages target mRNAs into ribonucleoprotein particles, controlling their transport, storage, stability and translation. It preferentially binds N6-methyladenosine (m6A)-modified transcripts, is highly expressed in embryonic tissues and many tumors, and is studied in development, cell migration and cancer.
| Target | Insulin-like growth factor 2 mRNA-binding protein 1 (gene IGF2BP1; UniProt Q9NZI8, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 63.5 kDa |
| Observed MW | 63 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.25 µg/mL (Human) |
|---|---|
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HepG2 cells, human Jurkat cells, human HEK293 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.25 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with a confirmed signal (flow cytometry): SiHa cells.
Immunogen
Recombinant human IMPI/IGF2BP1 fragment (Asn8–Gln562), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places insulin-like growth factor 2 mRNA-binding protein 1 in the nucleus, cytoplasm and cell projection. Tissue expression noted by UniProt (human): Mainly expressed in the embryo, including in fetal liver, fetal lung, fetal kidney, fetal thymus (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Bai-Shun Wan et al. (2019) Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer. World Journal of Gastroenterology. 10.3748/wjg.v25.i40.6063
